UNICA IRIS Institutional Research Information System

LANZOLLA, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.362
NA - Nord America 1.389
AS - Asia 1.098
SA - Sud America 249
Continente sconosciuto - Info sul continente non disponibili 153
OC - Oceania 103
AF - Africa 43
Totale 5.397
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.098
US - Stati Uniti d'America 1.335
SG - Singapore 341
CN - Cina 335
BR - Brasile 170
VN - Vietnam 143
AU - Australia 98
BD - Bangladesh 80
NL - Olanda 66
FI - Finlandia 50
HK - Hong Kong 46
IN - India 29
FR - Francia 27
CA - Canada 26
DE - Germania 26
ID - Indonesia 25
SE - Svezia 25
AR - Argentina 22
MX - Messico 21
KR - Corea 20
PE - Perù 17
GB - Regno Unito 15
EC - Ecuador 12
CO - Colombia 11
PL - Polonia 11
DZ - Algeria 9
JP - Giappone 9
TR - Turchia 9
JO - Giordania 8
ZA - Sudafrica 8
AT - Austria 7
MA - Marocco 7
TH - Thailandia 7
CL - Cile 6
IE - Irlanda 6
IQ - Iraq 6
MY - Malesia 6
RU - Federazione Russa 5
UA - Ucraina 5
ES - Italia 4
JM - Giamaica 4
KE - Kenya 4
MG - Madagascar 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
SA - Arabia Saudita 4
VE - Venezuela 4
BE - Belgio 3
IR - Iran 3
PK - Pakistan 3
PY - Paraguay 3
BO - Bolivia 2
EG - Egitto 2
ET - Etiopia 2
IL - Israele 2
KW - Kuwait 2
OM - Oman 2
PH - Filippine 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SB - Salomone, isole 1
SD - Sudan 1
TW - Taiwan 1
Totale 5.244
Salva come PNG Salva come JPEG
Città #
Cagliari 1.861
Dallas 212
Singapore 210
San Jose 125
Ashburn 107
Council Bluffs 85
Melbourne 75
Beijing 66
Los Angeles 58
Ho Chi Minh City 56
Hefei 51
Chicago 44
Hong Kong 39
Hanoi 37
Helsinki 37
Columbus 25
Amsterdam 23
São Paulo 23
Santa Clara 19
Seoul 19
Lauterbourg 18
New York 18
Salt Lake City 17
Heumen 16
Rome 16
Buffalo 15
Guangzhou 14
Hengelo 14
St Louis 14
Orem 13
Phoenix 13
Redondo Beach 13
Brooklyn 12
Lappeenranta 12
Philadelphia 12
Tortolì 12
Mexico City 11
Montreal 11
Milan 10
Warsaw 10
Atlanta 9
Boardman 9
Miami 9
Rende 9
Xi'an 9
Chennai 8
Frankfurt am Main 8
Houston 8
Lima 8
Rio de Janeiro 8
Sydney 8
Amman 7
Brisbane 7
Da Nang 7
Dublin 7
Jakarta 7
Maize 7
Queens 7
Selargius 7
Jacksonville 6
Mainz 6
Manchester 6
Casalecchio di Reno 5
Elk Grove Village 5
Johannesburg 5
Las Vegas 5
Naples 5
Nuremberg 5
Shenzhen 5
Tampa 5
Algiers 4
Antananarivo 4
Auckland 4
Augusta 4
Bangkok 4
Bogotá 4
Bologna 4
Brasília 4
Florence 4
Genoa 4
Guayaquil 4
Hercules 4
Hyderabad 4
Palermo 4
Porto 4
Sacramento 4
San Francisco 4
Santiago 4
Shenyang 4
Uta 4
Vienna 4
Agliana 3
Ankara 3
Baghdad 3
Bari 3
Belo Horizonte 3
Biên Hòa 3
Buenos Aires 3
Changzhou 3
Charlotte 3
Totale 3.761
Salva come PNG Salva come JPEG
Nome #
Graves disease: latest understanding of pathogenesis and treatment options 860
Oxidative phosphorylation in bone cells 437
Risk of Neck Hematoma Following Thyroidectomy in Patients Taking Direct Oral Anticoagulants: A Propensity Score Matching Analysis from Nine High-Volume European Centers (RAGNO Study) 262
Editorial: News in Graves’ orbitopathy: patients management and treatments 214
Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye Injection 184
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III) 172
Long-term outcome of Graves’ orbitopathy following treatment with sirolimus 156
Graves’ Disease: Is It Time for Targeted Therapy? A Narrative Review 152
HIF1 activation safeguards cortical bone formation against impaired oxidative phosphorylation 150
Osteoblastic erythropoietin is not required for bone mass accrual 149
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy 145
Ocular surface disease index in Graves’ orbitopathy: a cross-sectional study 135
Sirolimus as a second-line treatment for Graves’ orbitopathy 120
Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiency 119
Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease 107
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy 101
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women 100
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves’ Orbitopathy: A Retrospective Cohort Study 95
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-l1 blockade: Insights from four cases 94
Antioxidant Therapy in Graves’ Orbitopathy 87
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment 82
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 82
IgG4 serum levels in Graves’ orbitopathy 82
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ orbitopathy 75
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 70
Absence of a relationship between vitamin D and Graves’ orbitopathy 61
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy 60
Erythropoietin and skeletal cells crosstalks in physiology and disease 56
Insights into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 54
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 45
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy 45
Statins in Graves Orbitopathy: A New Therapeutic Tool 44
Immune checkpoint blockade Anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome 43
Oxidative Stress in Graves Disease and Graves Orbitopathy 42
Androgens and Hypertension in Men and Women: a Unifying View 42
Genetic Profiling of Orbital Fibroblasts from Patients with Graves' Orbitopathy 39
null 39
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 37
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 37
Early familial non-medullary thyroid cancer: differences with late-onset and sporadic forms 35
Statins: A New Hope on the Horizon of Graves Orbitopathy? 35
Graves’ disease and Graves’ orbitopathy following COVID-19 34
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 33
Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression 32
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk 31
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study 31
Occurrence of Graves’ hyperthyroidism and Graves’ orbitopathy after fine-needle aspiration biopsy of thyroid nodules 30
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 27
Does preoperative administration of Lugol’s solution in patients undergoing thyroidectomy for Graves’ disease really improve surgical outcomes? A propensity score matching analysis from six high-volume centers (StELLinA study) 26
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female 25
Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis 23
De-Escalating Thyroid Cancer Surgery: Insights and Unresolved Questions From the 2025 ATA Guidelines 20
Risk of Complications in Patients Undergoing Thyroidectomy for Graves' Disease (LUNA Study) 18
null 16
null 13
null 12
null 12
null 10
null 10
null 8
null 7
null 7
null 7
null 7
null 7
null 7
Totale 5.397
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.016
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.016
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.165 0 0 0 0 411 86 100 11 8 13 265 271
2025/20263.554 159 234 427 292 207 154 261 524 256 397 384 259
2026/2027678 436 242 0 0 0 0 0 0 0 0 0 0
Totale 5.397